The nature of immune dysregulation is markedly different between various MDS risk groups. In low-risk MDS, the immune system is in a proinflammatory state, whereas in high-risk disease ...

Rytelo is approved for low-risk MDS patients with transfusion-dependent anemia, excluding those with isolated deletion 5q. Phase 3 IMerge trial data demonstrated significant reduction in red blood ...

with its main rival considered to be Bristol-Myers Squibb's erythroid maturation agent Reblozyl (luspatercept), which was approved to treat anaemia in adults with low-risk, relapsed MDS in 2020 ...

MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with ...

If approved, it would compete with Bristol-Myers Squibb’s erythroid maturation agent Reblozyl (luspatercept), which was cleared to treat anaemia in adults with low-risk, relapsed MDS in 2020 and ...

low or intermediate risk myelodysplastic syndromes (lower-risk MDS or LR-MDS) without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ...